Details for Patent: 7,214,687
✉ Email this page to a colleague
Title: | Quinuclidine derivatives and medicinal compositions containing the same |
Abstract: | The invention provides 3 (R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1 -azoniabicyclo[2.2.2]octane in salt form, pharmaceutical compositions comprising it, and methods of using it for treatment of respiratory disorders, in association with phosphodiesterase 4 inhibitors. |
Inventor(s): | Fernandez Forner; Maria Dolors (Barcelona, ES), Prat Quinones; Maria (Barcelona, ES), Buil Albero; Maria Antonia (Barcelona, ES) |
Assignee: | Almirall AG (Baar, CH) |
Filing Date: | Jan 03, 2006 |
Application Number: | 11/324,919 |
Claims: | 1. A pharmaceutical composition comprising (i) 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2]octane wherein an anion X.sup.- is associated with the positive charge of the nitrogen atom and wherein X.sup.- is a pharmaceutically acceptable anion of a mono- or polyvalent acid; and (ii) a phosphodiesterase IV inhibitor. 2. The composition according to claim 1, wherein the anion X.sup.- is Br.sup.-. 3. A method for treating chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis which method comprises administering to a human or animal patient in need of such treatment an effective amount of: (i) 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2]octane wherein an anion X.sup.- is associated with the positive charge of the nitrogen atom and wherein X.sup.- is a pharmaceutically acceptable anion of a mono- or polyvalent acid; and (ii) a phosphodiesterase IV inhibitor. 4. The method according to claim 3, wherein the anion X.sup.- is Br.sup.-. |